Topic: chronic kidney disease
Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.
AstraZeneca is on its way to scoring a key new nod for SGLT2 diabetes drug Farxiga, and the FDA just sped things up.
If you'd popped into ADA, you might have thought you’d wandered into a kidney disease or NASH meeting. And that has drugmakers excited.
Invokana and its fellow SGLT2 drugs are all working to show benefits for kidney patients. But the J&J drug can tout data its rivals don’t have.
AZ may not yet have the same outcomes data for Farxiga that its SGLT2 rivals can boast, but the company thinks it may have something better.
When it comes to Invokana sales, J&J needs a way to stop the bleeding. And it just took a step closer to a new approval that could do just that.
Johnson & Johnson unveiled new data showing how its Invokana can benefit patients with Type 2 diabetes and chronic kidney disease.
AstraZeneca's latest diabetes awareness rollout features a fisherman who likens his stalling boat engine to a bad heart.
With China's large and increasing chronic kidney disease population, roxadustat could hit $1 billion in that country alone by 2025.
J&J’s Invokana will have to wait longer for the FDA to decide on a key label expansion, but it's still got good news to celebrate.